Your browser doesn't support javascript.
loading
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.
Menzies, Alexander M; Yeh, Iwei; Botton, Thomas; Bastian, Boris C; Scolyer, Richard A; Long, Georgina V.
Afiliação
  • Menzies AM; Melanoma Institute Australia, Sydney, NSW, Australia.
  • Yeh I; The University of Sydney, Sydney, NSW, Australia.
  • Botton T; Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Bastian BC; Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Scolyer RA; Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Long GV; Melanoma Institute Australia, Sydney, NSW, Australia.
Pigment Cell Melanoma Res ; 28(5): 607-10, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26072686
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / Neoplasias Cutâneas / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / Melanoma / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / Neoplasias Cutâneas / MAP Quinase Quinase Quinases / Proteínas Proto-Oncogênicas B-raf / Melanoma / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article